initial public offerings (IPOs) trading on American exchanges
Showing posts with label latest filings. Show all posts
Showing posts with label latest filings. Show all posts

Thursday, February 6, 2020

Warner Music Group files registration statement on Form S-1 for IPO

  • The shares of common stock to be sold in this offering are proposed to be sold by certain of Warner Music Group's stockholders. 


Warner Music Group Corp. filed plans for an initial public offering Thursday, 15 years after its last IPO and nine years after the company was taken private

Warner Music, one of three large companies that dominate the recorded-music industry, said in a filing with the Securities and Exchange Commission that it plans to seek $100 million in the IPO, though that is typically a placeholder amount that is updated in later filings. Warner is the parent company for prominent record labels including Atlantic Records, Warner Records and Elektra Records, and prominently mentioned artists Ed Sheeran, Bruno Mars, Cardi B, Twenty One Pilots, Lizzo and Katy Perry in its filing. Warner Music said that in its most recently completed fiscal year -- which ended Sept. 30, 2019 -- the company had profit of $258 million on revenue of $4.48 billion. In the two previous fiscal years, Warner Music respectively had net income of $312 million and $149 million, and revenue of $4.01 billion and $3.58 billion, according to the filing. After going public in 2005, Warner Musicwas taken private by Access Industries Inc. in 2011 for $3.3 billion. Rival Universal Music Group was valued at roughly $34 billion last year in investments from around the globe. Access will still have control of the company if it manages to go public, the company said in its IPO filing. The IPO is being led by Morgan Stanley, Credit Suisse and Goldman Sachs, and the filing did not list a prospective ticker symbol nor name the exchange on which the company intends to list its shares.

Monday, March 27, 2017

====Ionis (IONS) spinout Akcea files for $100M IPO



Ionis Pharmaceuticals’ lipid disorder subsidiary Akcea Therapeutics has filed for a $100 million IPO. The spinout has secured a $50 million stock purchase commitment from its partner Novartis, putting it on track to pull in cash to fund mid- and late-phase trials of four pipeline prospects.

Akcea is yet to set the terms of the IPO but its initial filing lists $100 million as the top end of its fundraising ambitions. In a year noted as much so far for thwarted IPOs as successful listings, that target could prove elusive for some companies. But Akcea, in keeping with many biotechs that have listed successfully since the IPO market slowed down, has already secured the support of a backer that is willing to buy a sizable slice of the offering.

If all goes to plan, Novartis will buy up $50 million worth of the IPO shares. The Swiss Big Pharma’s commitment dates back to the deal it struck with Akcea and its parent company Ionis in January. Among the components of that deal—the value of which could top out above $1 billion—was a promise by Novartis to invest $50 million in Ionis or Akcea within 18 months. Akcea is using that commitment to get book building for its IPO off to a flying start.

Lipid disorder specialist Akcea has earmarked the IPO funds for four trials. The top priority is to fund volanesorsen through to its commercial introduction in familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy (FPL), two rare genetic disorders characterized by problems with how the body handles triglycerides.

Ionis posted phase 3 data in patients with hypertriglyceridemia late last year, before following up with a readout from a trial of people with FCS earlier this month. Both studies linked volanesorsen to steep declines in triglyceride levels, but ongoing concerns about the safety of the antisense drug marred investor perceptions of the most recent readout. If volanesorsen comes to market, some of the IPO haul will go toward providing platelet monitoring to mitigate the risk of adverse events.

Other tranches of the anticipated cash boost will enable Akcea to take its two Novartis-partnered assets—AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx—through phase 2 trials. Once Novartis sees data from those studies, it will decide whether to exercise its option to license the the assets. Akcea also plans to spend money on a phase 2 trial of wholly-owned dyslipidemia candidate AKCEA-ANGPTL3-LRx.

Ionis stands to profit from the success of Akcea. The first payment of $15 million will come out of the IPO funds to cover a sublicensing agreement related to the $75 million upfront fee paid by Novartis. Down the line, Akcea will split licensing fees, milestones and royalties from Novartis 50-50 with Ionis. And Ionis will also retain an as-yet-undecided stake in Akcea.

Thursday, September 12, 2013

Twitter says it filed confidential IPO registration with U.S. Securities and Exchange Commission


  • Twitter to list on the NYSE on November 15, 2013


(Reuters) - Twitter Inc has filed for an initial public offering with U.S. regulators, the company said on Thursday, taking the first step toward what would be Silicon Valley's most anticipated debut since Facebook Inc's last year.

The impending IPO of the microblogging phenomenon ignited a competition among Wall Street's biggest names for the prestige of managing its coming-out party. Goldman Sachs is lead underwriter, a source familiar with the matter said on Thursday, which is a major coup for the Wall Street bank.

Twitter filed for an IPO confidentially under a 2012 law intended to help emerging corporations with less than $1 billion in revenue go public.


Its debut, though much smaller than Facebook's, could generate tens of millions of dollars in fees from the underwriting mandate itself. Assuming it sells around 10 percent of its shares, or $1 billion, underwriters could stand to divide a fee pool of $40 million to $50 million, assuming an overall fee cut of 4 percent to 5 percent, according to Freeman & Co.

But the benefits for banks that underwrite the deal would likely be far-reaching.

"Some companies will say, ‘We liked the way you handled Twitter, and we want to come to you first when we do our IPO,'" said David Menlow, president of IPOFinancial.com.

"It's not only bragging rights," Menlow said. "It's getting through the front door, which will line up banks for other transactions done after that, like debt financings and M&A."

Technology bankers at major banks from JPMorgan and Credit Suisse Group AG to Morgan Stanley had vied for coveted lead underwriting roles in the IPO. Several have had informal conversations with the micro-blogging network's management, sources familiar with the matter said.

A similar race is on around China's Alibaba, which is expected to raise more than $15 billion this year. Bank chief executives such as JPMorgan's Jamie Dimon and Citigroup Inc's Michael Corbat have made it a point to meet Alibaba founder Jack Ma.

PHENOM

Seven-year old Twitter, which allows users to send out streams of 140-character messages, has become an indispensable tool to governments, corporations and celebrities seeking to communicate with their audience, and for individuals seeking both news and entertainment.

Twitter, which has been valued by private investors at more than $10 billion, is on track to post $583 million in revenue in 2013, according to advertising consultancy eMarketer.

Max Wolff of Greencrest Capital estimated that Twitter would reach break-even this year, and that it is on track for 40 percent annual growth at a $1 billion annual revenue run rate.

"It's completely conquered mobile. It has an enormous social network. It's becoming a key utility as a second screen to TV and it's literally the first draft of history," Wolff said. "Normally a company like Twitter would have been public for some time."

Twitter is allowed to file its registration statement confidentially due to the Jumpstart Our Business Startups (JOBS) Act, a 2012 law that loosened some of the regulations surrounding the IPO process and other forms of capital raising.

Companies that file under that law do not have to reveal certain details until 21 days before embarking on an investor roadshow.

It could allow Twitter to avoid some of the harsh public scrutiny that other tech companies such as Groupon Inc faced. Groupon in 2011 was plagued by questions about its reliance on what some considered to be unusual accounting practices.

Wednesday, September 11, 2013

Software company Veeva files for IPO of up to $150 million

(Reuters) - Life sciences-focused software company Veeva Systems Inc filed with U.S. regulators to raise up to $150 million in an initial public offering of its common stock.

Veeva, which competes with Oracle Corp, provides web-based software for pharmaceutical representatives that allows them to track drug information and to provide documentation and data to their sales forces.

The company's clients include some of the biggest pharmaceutical companies in the world such as Novartis AG, Merck & Co Inc, Eli Lilly and Co and Bayer AG.

Reuters reported in April that Pleasanton, California-based Veeva was planning an IPO that could come in the third quarter.

Morgan Stanley and Deutsche Bank Securities are the lead underwriters for the IPO, Veeva told the U.S. Securities and Exchange Commission in a preliminary prospectus on Wednesday.

The filing did not reveal how many shares the company planned to sell or their expected price. (http://link.reuters.com/rym92v)

Veeva, which intends to list its common stock on the New York Stock Exchange under the symbol "VEEV," said that net proceeds from the offering would be used for working capital purposes.

The company, which received $4 million in funding from venture capital firm Emergence Capital Partners LP in 2008, reported a profit of $599,000 on revenue of $61.2 million in 2012.

Emergence Capital is Veeva's largest shareholder with a more than 30 percent stake.

The amount of money a company says it plans to raise in its first IPO filings is used to calculate registration fees. The final size of the IPO could be different.

Thursday, June 23, 2011

Latest Filings


North American Financial Holdings, Inc.06/23/11
Memorial Production Partners LP06/23/11
Clovis Oncology, Inc.06/23/11
LipoScience, Inc.06/23/11
PetroLogistics LP06/21/11
Imperva, Inc.06/17/11
Ubiquiti Networks, Inc.06/17/11
Oaktree Capital Group, LLC06/17/11
Enphase Energy, Inc.06/15/11
CafePress Inc.06/10/11